Medimpact

STANDARD COMMERCIAL DRUG FORMULARY PRIOR AUTHORIZATION GUIDELINES

CORTICOTROPIN

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
CORTICOTROPIN	ACTHAR ,	02830		GPI-10	FDB: ROUTE =
	CORTROPHIN			(3030001000)	INJECTION

GUIDELINES FOR USE

- 1. Does the patient have a diagnosis of infantile spasms and meet the following criterion?
 - The patient is less than 2 years of age

If yes, approve for 28 days by HICL or GPI-10 with a maximum of #8 vials (each 5mL vial contains 400 units).

If no, continue to #2.

2. Is the request for any other indications other than infantile spasms?

If yes, do not approve. See note and use denial text below. Note: Off-label guideline should not be used for Acthar because it hasn't demonstrated proven benefits in the other indications and has no proven advantage over synthetic steroids. Therefore, there isn't a pathway to approval for any other listed indications.

If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **CORTICOTROPIN (Acthar, Cortrophin)** requires the following rule(s) be met for approval:

- A. You have infantile spasms (type of seizure disorder in young children)
- B. You are less than 2 years of age

Acthar will not be approved for any other indications other than infantile spasms. Acthar has not demonstrated proven benefits or advantage over synthetic steroids in the treatment of other indications.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Medimpact

STANDARD COMMERCIAL DRUG FORMULARY PRIOR AUTHORIZATION GUIDELINES

CORTICOTROPIN

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Acthar.

REFERENCES

• Acthar Gel [Prescribing Information]. Bedminster, NJ: Mallinckrodt ARD LLC; April 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A Commercial Effective: 01/01/23 Created: 11/07 Client Approval: 11/22

P&T Approval: 04/20

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.